{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:05:14Z","timestamp":1785801914404,"version":"3.56.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To review the pharmacology, efficacy, and safety of ibrexafungerp in the management of vulvovaginal candidiasis (VVC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>Literature was sought using PubMed (1966\u2014February 2022) and EMBASE (1973\u2014February 2022), and clinicaltrials.gov. Search terms included ibrexafungerp, SCY-078, and VVC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>All studies including humans and published in English with data assessing the efficacy and safety of ibrexafungerp for the treatment of VVC were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>A phase 2 dose-finding study found ibrexafungerp had similar efficacy to fluconazole in the clinical cure of VVC (51.9% vs 58.3%, respectively). Two phase 3 clinical trials demonstrated ibrexafungerp had statistical superiority over placebo for clinical cure in moderate to severe VVC ( P &lt; 0.001 and P = 0.023, respectively). The most frequently reported adverse reactions in the clinical trials were gastrointestinal-related symptoms. To date, data comparing efficacy of ibrexafungerp and topical imidazoles in the treatment of VVC are nonexistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice<\/jats:title>\n                    <jats:p>Topical imidazoles and oral fluconazole are effective for the treatment of uncomplicated VVC. Due to increased resistance, limited fluconazole coverage for non- Candida albicans species, and potential for significant drug interactions associated with fluconazole use, alternative treatments for VVC are needed. Ibrexafungerp is a new oral triterpenoid antifungal agent indicated for the treatment of VVC. Additional clinical trials are needed to evaluate long-term safety data as well as efficacy and safety in specialty populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ibrexafungerp, a recently approved triterpenoid antifungal agent, is an effective and well-tolerated option for the treatment of VVC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221091301","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T01:57:36Z","timestamp":1651543056000},"page":"99-106","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis"],"prefix":"10.1177","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1060-5164","authenticated-orcid":false,"given":"Kylie N.","family":"Barnes","sequence":"first","affiliation":[{"name":"Division of Pharmacy Practice and Administration, University of Missouri\u2014Kansas City School of Pharmacy, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail M.","family":"Yancey","sequence":"additional","affiliation":[{"name":"Pharmacy Practice, University of Health Sciences and Pharmacy, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia B.","family":"Forinash","sequence":"additional","affiliation":[{"name":"Pharmacy Practice, University of Health Sciences and Pharmacy, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"bibr1-10600280221091301","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7004a1."},{"key":"bibr2-10600280221091301","unstructured":"Food and Drug Administration. Antifungal resistance in\n                      Candida\n                      . Accessed February 17, 2022. https:\/\/www.cdc.gov\/fungal\/diseases\/candidiasis\/antifungal-resistant.html#:~:text=About%207%25%20of%20all%20Candida,Candida%20glabrata%2C%20and%20Candida%20parapsilosis."},{"key":"bibr3-10600280221091301","unstructured":"Diflucan (fluconazole) [package insert]. New York, NY: Pfizer, Inc; 2021. Accessed February 1, 2022. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?format=PDF&id=575."},{"key":"bibr4-10600280221091301","doi-asserted-by":"publisher","DOI":"10.1097\/aog.0b013e31827307b2."},{"key":"bibr5-10600280221091301","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.00011.x"},{"key":"bibr6-10600280221091301","unstructured":"Brexafemme (ibrexafungerp) [package insert]. Jersey City, NJ: SCYNEXIS, Inc; 2021. Accessed February 17, 2022. https:\/\/d1io3yog0oux5.cloudfront.net\/scynexis\/files\/pages\/scynexis\/db\/pis\/Digital+Ibrexafungerp+Prescribing+Information+%28PI%29.pdf."},{"key":"bibr7-10600280221091301","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9090539."},{"key":"bibr8-10600280221091301","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02611-18."},{"key":"bibr9-10600280221091301","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000383."},{"key":"bibr10-10600280221091301","volume-title":"Performance Standards for Antifungal Susceptibility Testing of Yeasts","author":"Clinical and Laboratory Standards Institute","year":"2020","edition":"2"},{"key":"bibr11-10600280221091301","unstructured":"Food and Drug Administration. NDA Multi\u2014disciplinary review and evaluation\u2014NDA 214900 (Brexafemme) October 12, 2018. Accessed February 1, 2022. https:\/\/www.fda.gov\/media\/151040\/download."},{"key":"bibr12-10600280221091301","unstructured":"Food and Drug Administration.\n                      Candida auris\n                      : antifungal susceptibility testing. Accessed February 17, 2022. https:\/\/www.cdc.gov\/fungal\/candida-auris\/c-auris-antifungal.html."},{"key":"bibr13-10600280221091301","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab841."},{"key":"bibr14-10600280221091301","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab750."},{"key":"bibr15-10600280221091301","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16972."},{"key":"bibr16-10600280221091301","unstructured":"ClinicalTrials.gov. Phase 3 study of oral ibrexafungerp (SCY-078) vs. placebo in subjects with recurrent vulvovaginal candidiasis (VVC) (CANDLE). Accessed February 15, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04029116."},{"key":"bibr17-10600280221091301","unstructured":"SCYNEXIS. SCYNEXIS presents interim analysis from FURI at virtual IDWeek 2021 showing favorable therapeutic response in severe hospital-based fungal infections treated with oral ibrexafungerp. Accessed February 15, 2022. https:\/\/www.scynexis.com\/news-media\/press-releases\/detail\/254\/scynexis-presents-interim-analysis-from-furi-at-virtual."},{"key":"bibr18-10600280221091301","first-page":"0815","volume":"2015","author":"Martin Lopez JE","year":"2015","journal-title":"BMJ Clin Evid"},{"key":"bibr19-10600280221091301","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002845.pub3."},{"key":"bibr20-10600280221091301","doi-asserted-by":"publisher","DOI":"10.1159\/000338899."},{"key":"bibr21-10600280221091301","unstructured":"Food and Drug Administration. FDA drug safety communication: use of long-term, high-dose Diflucan (fluconazole) during pregnancy may be associated with birth defects in infants. Accessed February 17, 2022. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communicationuse-long-term-high-dose-diflucan-fluconazole-during-pregnancy-may-be."},{"key":"bibr22-10600280221091301","unstructured":"Ibrexafungerp. Lexi-Drugs. Hudson, OH: Lexicomp;2021. Accessed February 17, 2022. http:\/\/online.lexi.com\/."},{"key":"bibr23-10600280221091301","unstructured":"Fluconazole. Lexi-Drugs. Hudson, OH: Lexicomp;2021. Accessed February 17, 2022. http:\/\/online.lexi.com\/."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221091301","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221091301","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221091301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:50Z","timestamp":1777375010000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221091301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1177\/10600280221091301"],"URL":"https:\/\/doi.org\/10.1177\/10600280221091301","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]}}}